• Qiqiang Zeng, Qiyu Zhang, Shaoliang Han, Zhengping Yu, Minghua Zheng, Mengtao Zhou, Jianling Bai, and Rong Jin.
• Department of General Surgery, First Affiliated Hospital, Wenzhou Medical College, Wenzhou, Zhejiang Province, China.
• Pancreas. 2008 Jan 1;36(1):18-25.

ObjectiveThe aim of this study was to evaluate the efficacy of somatostatin and its analogues in prevention of postoperative complications after pancreaticoduodenectomy.MethodsA literature search of the MEDLINE, EMBASE, and Cochrane databases was used to identify randomized controlled trials that compared somatostatin and its analogues with control group after pancreaticoduodenectomy. Meta-analytical techniques were applied to identify differences in outcomes between the 2 groups.ResultsA total of 8 studies were identified according to our inclusion criteria, including 2 studies using somatostatin, 5 studies using octreotide, and 1 study using vapreotide. The use of somatostatin or its analogues did not significantly benefit for reducing the incidence of pancreatic fistula (odds ratio [OR] 95% confidence interval [CI], 0.64-1.37; P = 0.73), total pancreas-specific postoperative complications (OR 95% CI, 0.63-1.42; P = 0.79), delayed gastric emptying (OR 95% CI, 0.50-1.78; P = 0.86), total complication (OR 95% CI, 0.73-1.70; P = 0.61), mortality (OR 95% CI, 0.59-7.72; P = 0.97), and length of postoperative hospital stay (weighted mean difference 95% CI, -7.74 to 4.47; P = 0.60).ConclusionsThe use of somatostatin and its analogues does not significantly reduce postoperative complications after pan-creaticoduodenectomy.

18 keywords...

hide…